About pharma mar sa - PHMMF
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.
PHMMF At a Glance
Pharma Mar SA
Avenida de los Reyes, 1
Colmenar Viejo, Madrid 28770
| Phone | 34-91-846-60-00 | Revenue | 170.98M | |
| Industry | Pharmaceuticals: Other | Net Income | 1.23M | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
PHMMF Valuation
| P/E Current | 1,878.72 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 660.539 |
| Price to Sales Ratio | 4.755 |
| Price to Book Ratio | 3.746 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1,552.282 |
| Enterprise Value to Sales | 3.985 |
| Total Debt to Enterprise Value | 0.07 |
PHMMF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 3.236 |
| Total Asset Turnover | 0.429 |
PHMMF Liquidity
| Current Ratio | 2.634 |
| Quick Ratio | 2.225 |
| Cash Ratio | 1.695 |
PHMMF Profitability
| Gross Margin | 91.595 |
| Operating Margin | -3.383 |
| Pretax Margin | -2.291 |
| Net Margin | 0.719 |
| Return on Assets | 0.308 |
| Return on Equity | 0.544 |
| Return on Total Capital | 0.47 |
| Return on Invested Capital | 0.479 |
PHMMF Capital Structure
| Total Debt to Total Equity | 22.42 |
| Total Debt to Total Capital | 18.314 |
| Total Debt to Total Assets | 12.71 |
| Long-Term Debt to Equity | 14.922 |
| Long-Term Debt to Total Capital | 12.189 |